Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an education grant from Novartis Pharmaceuticals Corporation.

Community Practice Connections™: Navigating the Latest Evidence to Optimize Utilization of Novel Therapies in R/R CML

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. The treatment landscape of CML was transformed in 2001 with the approval of imatinib, the first BCR-ABL tyrosine kinase inhibitor (TKI) to be used in the management of this disease, and 5 TKIs are now approved for the treatment of chronic-phase CML. Overall, the 5-year survival rate for all patients with CML has more than tripled, up from 22% in the mid-1970s to nearly 70% at present.

Community Practice Connections™: Navigating the Latest Evidence to Optimize Utilization of Novel Therapies in R/R CML consists of a series of short summaries of recent clinical data and short video interviews with leading experts in CML, addressing questions commonly faced in the community oncology practice setting. This activity will focus on practical challenges facing clinicians who treat patients with CML, including individualizing TKI selection, monitoring patients for response to therapy, treating patients with relapsed/refractory disease, sequencing available therapies most effectively, and managing adverse effects associated with TKI therapy.

Acknowledgement of Commercial Support

This activity is supported by an education grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward academic and community-based hematologists, oncologists, pathologists, histologists, nurse practitioners, pharmacists, physician assistants, and other health care professionals involved in the treatment of patients with chronic myeloid leukemia.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss efficacy and safety evidence concerning the application of tyrosine kinase inhibitor (TKI) therapies in the management of patients with relapsed/refractory chronic myeloid leukemia (CML)
Assess recent results from clinical trials conducted among patients with CML that assessed the effectiveness of TKIs and methods to stratify risk for resistance in the context of therapeutic switching
Determine effective strategies to ensure TKI adherence via proactive risk stratification for toxicities and management of treatment-associated toxicities
Integrate approaches that allow practitioners to demonstrate confidence on practical methods to personalize care and optimize the application of TKI treatment strategies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Jerald P. Radich, MD
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
University of Washington School of Medicine
Seattle, WA

Disclosures: Consultant: Novartis, Amgen, BMS, Genentech

Faculty

Gabriela Hobbs, MD
Clinical Director, Leukemia Service,
Massachusetts General Hospital,
Boston, MA
Assistant Professor,
Harvard Medical School,
Boston, MA

Disclosures: Dr. Gabriela Hobbs has no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.